Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative Chemoradiation in Locally Advanced NSCLC (TROG 03.07)
NCT00193921Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Feb 2003
- Primary completion
- Dec 2009
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vinorelbine and Cisplatin micelle injection (HA132) in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: Objective Response Rate at 1 year, Symptomatic Response Rate at 1 year and 2 more. Started Feb 2003; status: completed.
02
Drugs
vinorelbineCisplatin micelle injection (HA132)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00193921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193921.